NCT03133273View on ClinicalTrials.gov

Study of the Therapeutic Response and Survival of Patients with Metastatic Colorectal Cancer (stage IV) and Treated According to the Guidelines of a Chemosensitivity Test, Oncogramme® (ONCOGRAM)

NACompletedINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

July 24, 2017

Primary Completion Date

April 3, 2024

Study Completion Date

April 3, 2024

Conditions
Colorectal Cancer MetastaticChemotherapy
Interventions
OTHER

Oncogramme®

Patient is followed within the usual care for stage 4 colorectal cancer, but an Oncogramme test will be made and chemotherapy will be adapted to the results.

Trial Locations (13)

19100

Clinique des Cédres, Brive-la-Gaillarde

23000

Hospital Center, Guéret

Centre Médical MGEN Alfred Leune, Sainte-Feyre

30029

Nimes University Hospital, Nîmes

33076

Bergonié Institut, Bordeaux

37170

CHU de TOURS, Chambray-lès-Tours

63003

Clermont-Ferrand University Hospital, Clermont-Ferrand

67000

CHU de Strasbourg, Strasbourg

80054

CHU d'AMIENS, Amiens

86021

CHU de POITIERS, Poitiers

87042

Limoges University Hospital, Limoges

87200

CH de Saint Junien, Saint-Junien

97261

CHu de la Martinique, Fort-De-France

Sponsors

Collaborators (1)

Oncomédics
All Listed Sponsors
collaborator

Oncomédics

UNKNOWN

lead

University Hospital, Limoges

OTHER

NCT03133273 - Study of the Therapeutic Response and Survival of Patients with Metastatic Colorectal Cancer (stage IV) and Treated According to the Guidelines of a Chemosensitivity Test, Oncogramme® (ONCOGRAM) | Biotech Hunter | Biotech Hunter